alone, 0.20 for radiation with A620223 at a dose of 6.25 mg/kg/day, and 0.04 for radiation at 12.5 mg/kg/day. This represents a significant difference for the lower ($p=0.036$) and higher ($p=0.003$) dosing arms with radiation when compared to radiation alone.

Conclusions: The novel PARP inhibitor A620223 has a strong dose-dependent radio-enhancing effect in the nude mouse HCT116 xenograft model. This experiment supports ongoing efforts at rational drug design in potentiating the effects of radiation. Further preclinical investigations are underway with A620223 and other PARP inhibhitors are in development in early phase trials.



Author Disclosure: B. Hristov, None; T.L. DeWeese, None; L.E. Dillehay, Abbott Laboratories, B. Research Grant; D. Frost, Abbott Laboratories, A. Employment; L.R. Kleinberg, None.

128 Prediction of Antitumor Activity of PR-104, a New Hypoxia Activated Mustard, Using Measurements of DNA Interstrand Crosslinks by the Comet Assay

Mary Jo Dorie[1], G-one Ahn[1], Douglas Menke[1], Rachelle Douglas[2], Bronwyn Siim[2], Adam Patterson[2], William Wilson[2], Martin Brown[1]

[1]Stanford University, Stanford, CA, USA, [2]University of Auckland, Auckland, New Zealand

Full abstract will be published in the Radiation Research Society's Final Program.

129 The Effect of Dose and Timing of an ACE Inhibitor, Ramipril, on Mitigation of Radiation-Induced Optic Neuropathy in Rats

Jae Ho Kim[1], Stephen L. Brown[1], Andrew Kolozsvary[1], Kenneth A. Jenrow[2], Samuel Ryu[1]

[1]Radiation Oncology, Henry Ford Health System, Detroit, MI, USA, [2]Neurosurgery, Henry Ford Health System, Detroit, MI, USA

Full abstract will be published in the Radiation Research Society's Final Program.

130 Enhanced Radiation Response in A549 Human Lung Cancer of Nude Mice by Cytotoxic RNase, Rapirnase, by Improved Tumor Physiology

Dae H. Kim, Sergey Magnistsky, Intae Lee

University of Pennsylvania, Philadelphia, PA, USA

Full abstract will be published in the Radiation Research Society's Final Program.

131 Effects of Repeated EFAPROXYN™ (Efaproxiral) Dosing, an Allosteric Hemoglobin Modifier, on Oxygenation and Enhancement of Radiotherapy in Subcutaneous RIF-1 Tumors, in Mice

Huagang Hou[1], Nadeem Khan[1], Oleg Grinberg[1], Hongsheng Yu[1], Shiyi Lu[1], Eugene Demidenko[1], Robert P. Steffen[2], Harold M. Swartz[1]

[1]Radiology, Dartmouth Medical School, Hanover, NH, USA, [2]Allos Therapeutics, Inc, Westminster, CO, USA

Full abstract will be published in the Radiation Research Society's Final Program.